Center for Infectious Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Beijing Key Laboratory of AIDS Research, Beijing, China.
Front Immunol. 2021 Feb 17;12:632119. doi: 10.3389/fimmu.2021.632119. eCollection 2021.
HIV infection results in immune homeostasis perturbations, which is characterized by CD4 T-cell depletion, immune activation, and inflammation. Effective antiretroviral therapy (ART) does not fully restore immunologic and clinical health in people living with HIV (PLWH). Various drugs have been used to improve their immune status and CD4 T-cell counts, but no measures have been tested effective. Here we conduct a systematic review and meta-analysis of existing clinical studies on improving CD4 T-cell count while decreasing inflammation and immune activation. We retrieved possible relevant publications from a total of five electronic databases and selected eligible studies, which dealt with outcomes of medical therapy for CD4 T-cell count recovery, inflammation, and immune activation with or without ART. We paid particular attention to immunologic non-responders with a favorable treatment regimen. Thirty-three articles were included in the systematic review and meta-analysis. However, there were no safe and effective medications specific for improving CD4 T-cell reconstitution. The immunological benefits or adverse events mainly depend on the safety, dosage, and duration of the candidate medication use, as well as whether it is combined with ART. Under the "safe, combined, adequate and long (SCAL)" principles, alternative approaches are needed to accelerate the recovery of CD4 T-cells, and to prevent adverse long-term outcomes in PLWH with standard ART treatment.
HIV 感染导致免疫稳态紊乱,其特征是 CD4 T 细胞耗竭、免疫激活和炎症。有效的抗逆转录病毒疗法(ART)并不能完全恢复 HIV 感染者(PLWH)的免疫和临床健康。已经使用了各种药物来改善他们的免疫状态和 CD4 T 细胞计数,但没有措施被证明是有效的。在这里,我们对现有的关于改善 CD4 T 细胞计数、降低炎症和免疫激活的临床研究进行了系统评价和荟萃分析。我们从五个电子数据库中总共检索了可能相关的出版物,并选择了符合条件的研究,这些研究涉及 CD4 T 细胞计数恢复、炎症和免疫激活的医学治疗结果,无论是否联合 ART。我们特别关注免疫无应答者的有利治疗方案。共有 33 篇文章被纳入系统评价和荟萃分析。然而,目前还没有专门用于改善 CD4 T 细胞重建的安全有效的药物。免疫获益或不良事件主要取决于候选药物使用的安全性、剂量和持续时间,以及是否与 ART 联合使用。在“安全、联合、充分和长期(SCAL)”原则下,需要采取替代方法来加速 CD4 T 细胞的恢复,并预防接受标准 ART 治疗的 PLWH 的不良长期后果。